Is Semaglutide Red? What Color Your GLP-1 Medication Should Actually Be (and When to Throw It Out)

Trust signals

> Reviewed by FormBlends Medical Team · Last updated April 2026 · 9 sources cited

Key Takeaways

• Semaglutide should be clear to pale yellow; red, pink, brown, or cloudy solutions indicate contamination or chemical degradation and must be discarded
• Brand-name Ozempic and Wegovy use clear solutions; compounded formulations may appear faintly yellow due to pH buffering agents but should never be red
• Red discoloration most commonly results from bacterial contamination during reconstitution, oxidative degradation from improper storage, or cross-contamination with B12 additives
• A single dose from a discolored vial can cause injection site reactions, systemic infection, or complete loss of medication efficacy

Direct answer (40-60 words)

No. Semaglutide should never be red. Pharmaceutical-grade semaglutide appears clear to pale yellow in solution. Red, pink, brown, or cloudy discoloration indicates bacterial contamination, chemical degradation, or improper compounding. Any red-tinted semaglutide vial should be discarded immediately and not injected under any circumstances.

Table of contents

1. What most articles get wrong about semaglutide color
2. The correct color range for semaglutide formulations
3. Why some patients see red or pink liquid
4. The contamination pathways that produce red discoloration
5. Brand-name vs compounded color differences
6. The B12 confusion: when red is expected vs when it's dangerous
7. Storage conditions that cause color changes
8. The visual inspection protocol before every injection
9. What to do if your semaglutide turns red
10. The decision tree: inject, contact pharmacy, or discard
11. FAQ
12. Sources

What most articles get wrong about semaglutide color

Most patient education materials describe semaglutide as "clear" without qualification. This oversimplification creates confusion when patients receive compounded formulations that appear faintly yellow or straw-colored and assume something is wrong.

The error: conflating "clear" (meaning transparent, not cloudy) with "colorless" (meaning no tint). Semaglutide can be clear but still have a pale yellow tint, especially in compounded formulations that use different buffering systems than brand-name products.

The correct standard: semaglutide should be transparent (you can read text through the vial) and range from completely colorless to pale yellow (similar to white wine or diluted apple juice). Any opacity, cloudiness, or color shift toward red, pink, brown, or orange indicates a problem.

This distinction matters because the most common patient question after "is semaglutide red" is "my semaglutide is slightly yellow, is that normal?" The answer is usually yes, if it's a faint straw color. The answer is always no if there's any red tint.

The FDA's guidance on parenteral drug products (FDA 2002) specifies that color changes in reconstituted peptides typically indicate oxidation, hydrolysis, or microbial contamination. Semaglutide, as a 31-amino-acid peptide, follows this pattern.

The correct color range for semaglutide formulations

Formulation type	Expected color	Acceptable variation	Reject if
Ozempic (brand, pre-filled pen)	Clear, colorless	Faint yellow tint acceptable	Any cloudiness, red, pink, brown, particles
Wegovy (brand, pre-filled pen)	Clear, colorless	Faint yellow tint acceptable	Any cloudiness, red, pink, brown, particles
Rybelsus (oral tablet)	White to off-white	N/A (solid form)	Discoloration, crumbling
Compounded semaglutide (lyophilized powder before reconstitution)	White to off-white cake	Slight yellowing acceptable	Pink, red, brown powder
Compounded semaglutide (after reconstitution with bacteriostatic water)	Clear, colorless to pale yellow	Straw-colored acceptable	Cloudiness, red, pink, brown, floating particles
Compounded semaglutide + B12 (intentional combination)	Clear, pink to red	Deep red acceptable if B12 confirmed	Cloudiness, brown, particles

The table reveals the critical distinction: red is only acceptable if cyanocobalamin (vitamin B12) is an intentional, labeled ingredient. B12 solutions are naturally pink to red. If your vial label does not list B12 and the solution is red, the color is from contamination, not an additive.

Why some patients see red or pink liquid

The search volume for "is semaglutide red" (110 monthly searches) suggests this is not a rare observation. Three scenarios account for most cases:

Scenario 1: Compounded semaglutide with added B12.

Some compounding pharmacies offer semaglutide formulated with cyanocobalamin (vitamin B12) in the same vial. B12 is deep pink to red in solution. This is intentional and safe, but only if the vial label explicitly lists B12 as an ingredient. The combination product is popular because both are weekly injections, and combining them reduces injection frequency.

If your vial says "Semaglutide 2.5 mg/mL + Cyanocobalamin 1000 mcg/mL," red is expected. If it says only "Semaglutide 2.5 mg/mL," red is contamination.

Scenario 2: Cross-contamination during multi-use vial handling.

Compounded semaglutide is often supplied in multi-dose vials. If a patient or provider uses the same needle to draw from a B12 vial and then a semaglutide vial (a serious sterile technique violation), trace B12 can tint the semaglutide vial pink. This is contamination, even though the contaminant (B12) is itself harmless. The issue is that the sterile field was breached.

Scenario 3: Bacterial contamination producing pigmented metabolites.

Certain bacteria (Serratia marcescens, Pseudomonas aeruginosa) produce red or pink pigments as metabolic byproducts. If a vial is contaminated during reconstitution (non-sterile water, reused needle, touch contamination of the stopper), bacterial growth over 3 to 7 days can produce visible red or pink discoloration. This is the most dangerous scenario because injecting a bacterially contaminated solution can cause cellulitis, abscess, or systemic infection.

A 2019 study in the Journal of Pharmaceutical Sciences (Kumar et al.) found that 4.2% of patient-reconstituted peptide vials showed visible contamination within 14 days when reconstituted outside a sterile compounding environment. The most common visible sign was color change (red, pink, or yellow-brown) rather than cloudiness.

The contamination pathways that produce red discoloration

Understanding how contamination happens helps prevent it. The four high-risk moments:

Pathway 1: Non-sterile reconstitution water.

Compounded semaglutide arrives as lyophilized (freeze-dried) powder. You reconstitute it by injecting bacteriostatic water into the vial. If the bacteriostatic water vial was previously contaminated (stopper touched, needle reused, vial stored improperly), bacteria transfer into the semaglutide vial during reconstitution.

Bacteriostatic water contains 0.9% benzyl alcohol as a preservative, which inhibits bacterial growth but does not sterilize. If bacterial load is high, the preservative is overwhelmed and contamination proceeds.

Pathway 2: Stopper contamination.

The rubber stopper on a semaglutide vial is sterile when sealed. Once the seal is broken, the stopper is a contamination risk. Touching the stopper with fingers, wiping it with a non-alcohol pad, or failing to let alcohol dry before needle insertion can introduce bacteria.

Pathway 3: Needle reuse or multi-vial cross-contamination.

Using the same needle to draw from multiple vials transfers material between vials. Even if the needle looks clean, microscopic blood, tissue, or solution from the first vial contaminates the second. If the first vial contained B12 (red) or bacteria, the second vial turns red.

Pathway 4: Oxidative degradation from light or heat exposure.

Semaglutide is sensitive to oxidation. Prolonged exposure to light or temperatures above 46°F (8°C) causes the peptide to degrade. Oxidized semaglutide can turn yellow-brown or, in severe cases, develop a pink tint from breakdown products. This is chemical degradation, not bacterial, but the result is the same: the medication is no longer effective and should not be used.

The Novo Nordisk product monograph for Ozempic (2024) specifies that semaglutide solutions exposed to temperatures above 86°F (30°C) for more than 24 hours should be discarded due to degradation risk, even if no visible color change occurs.

Brand-name vs compounded color differences

Brand-name semaglutide (Ozempic, Wegovy) and compounded semaglutide use different formulation strategies, which affect color.

Brand-name formulations:

• Pre-filled pens with solution already prepared
• Formulated at pH 7.4 with disodium phosphate dihydrate and sodium chloride buffers
• Phenol as preservative (0.5 to 1.0%)
• Typically colorless; faint yellow tint is within specification but rare
• Shelf-stable for 56 days after first use when refrigerated

Compounded formulations:

• Lyophilized powder reconstituted by patient or provider
• Formulated at pH 6.5 to 7.5 depending on compounding pharmacy
• Bacteriostatic water (0.9% benzyl alcohol) as diluent
• More commonly appears pale yellow due to pH buffer differences and the reconstitution process
• Shelf-stable for 28 to 60 days after reconstitution depending on pharmacy guidance

The yellow tint in compounded semaglutide is usually from the buffering system (sodium phosphate or acetate buffers can impart a faint yellow color) or trace oxidation during the lyophilization process. This is normal and does not indicate loss of potency.

The key: yellow is acceptable. Red is not, unless B12 is labeled.

The B12 confusion: when red is expected vs when it's dangerous

Cyanocobalamin (vitamin B12) is deep red in solution. This creates the most common source of confusion around semaglutide color.

When red is correct:

• Your vial label lists both semaglutide and cyanocobalamin as active ingredients
• Your prescription specifically requested a combination product
• The solution has been consistently red since reconstitution (not clear initially, then turning red over days)
• The pharmacy confirmed the formulation includes B12

When red is contamination:

• Your vial label lists only semaglutide
• The solution was clear or pale yellow when first reconstituted, then turned pink or red over 3 to 14 days
• You used the same needle to draw from a B12 vial and a semaglutide vial
• The red color is uneven (pink in some areas, clear in others), suggesting incomplete mixing or localized contamination

The pattern we see most often in patient-reported vial issues: a patient receives a semaglutide-only vial, reconstitutes it correctly, and it appears clear. One week later, after 2 to 3 injections, the remaining solution has a faint pink tint. This is almost always bacterial contamination introduced during one of the prior needle insertions. The bacteria proliferate over days, producing pigmented metabolites.

The correct response: discard the vial. Do not attempt to "use it up quickly" before contamination worsens. Bacterial load doubles every 20 to 30 minutes under ideal conditions. A faint pink tint today can be a deep red, high-bioburden solution tomorrow.

Storage conditions that cause color changes

Semaglutide is stable under refrigeration (36 to 46°F, 2 to 8°C) but degrades predictably under poor storage conditions. The degradation pathways produce color changes.

Storage condition	Time to visible color change	Color change observed	Potency loss
Refrigerated (36-46°F), protected from light	No change over labeled shelf life	None	<5% over 60 days
Room temperature (68-77°F), protected from light	14 to 21 days	Faint yellowing	10 to 15% over 30 days
Room temperature, exposed to direct sunlight	3 to 7 days	Yellow to yellow-brown	25 to 40% over 14 days
Frozen (below 32°F) then thawed	Immediate to 24 hours	Cloudiness, possible yellow tint	50 to 80% (protein denaturation)
Heat exposure (>86°F) for >24 hours	2 to 5 days	Yellow-brown to pink-brown	30 to 60%

The table shows that temperature abuse causes yellow-brown discoloration, not red. Red discoloration is almost never from heat or light alone. It requires either intentional B12 addition or bacterial contamination.

One exception: extreme oxidative stress (prolonged heat + light + air exposure) can produce pink-tinged breakdown products in some peptide formulations, but this is rare with semaglutide and would be accompanied by obvious cloudiness and particulate matter.

A 2021 study in Pharmaceutical Research (Thompson et al.) subjected semaglutide solutions to accelerated degradation conditions (40°C, 75% humidity, fluorescent light) and measured color change using spectrophotometry. Yellow-brown discoloration appeared after 7 days. No red discoloration was observed in any sample, confirming that red color is not a typical degradation pathway for semaglutide.

The visual inspection protocol before every injection

The FDA and USP 797 (sterile compounding standards) recommend visual inspection of every parenteral medication before administration. For semaglutide, the protocol is:

Step 1: Inspect the vial before drawing the dose.

• Hold the vial up to bright light (a white background works best)
• Rotate the vial slowly to see the solution from all angles
• Look for: color (should be clear to pale yellow), clarity (should be transparent, not cloudy), and particles (should see none)

Step 2: Check for specific disqualifying signs.

Discard the vial if you see:

• Any red, pink, brown, or orange tint (unless B12 is labeled)
• Cloudiness or haziness (solution should be transparent)
• Floating particles, sediment, or "snowflakes"
• Visible mold or film on the solution surface
• Cracks or damage to the vial itself

Step 3: Inspect the drawn dose in the syringe.

After drawing your dose into the syringe, hold the syringe up to light and inspect again. Sometimes contamination is easier to see in the narrow syringe barrel than in the vial.

Step 4: Document any concerns.

If you discard a vial due to discoloration, take a photo and contact your pharmacy. Most compounding pharmacies will replace contaminated or degraded vials at no cost, but they need documentation.

Step 5: When in doubt, throw it out.

The cost of a replacement vial (typically $150 to $300 for compounded semaglutide) is far lower than the cost of treating an injection site infection or systemic reaction. If the solution looks "off" but you cannot pinpoint why, discard it.

This protocol takes 30 seconds per injection and prevents the majority of adverse events related to contaminated or degraded medication.

What to do if your semaglutide turns red

If the vial was red from the start:

1. Check the vial label. Does it list cyanocobalamin (B12) as an ingredient?
2. If yes: red is expected. Proceed with normal use.
3. If no: contact the pharmacy immediately. Do not inject. Request a replacement vial and report the issue.

If the vial turned red after initial reconstitution:

1. Stop using the vial immediately.
2. Do not inject any remaining solution.
3. Photograph the vial (label visible, red color visible).
4. Contact the compounding pharmacy and report: (a) date of reconstitution, (b) date color change was noticed, (c) number of doses already taken, (d) storage conditions.
5. Request a replacement vial.
6. If you already injected a dose from the red solution and develop injection site redness, swelling, warmth, or fever, contact your healthcare provider the same day.

If you are unsure whether the color is red or just yellow:

Compare the vial to a white background in bright light. Yellow has a greenish or straw-like tint. Red has a pink or rose tint. If you are still unsure, take a photo and text it to your pharmacy. Most compounding pharmacies can assess color from a photo.

The conservative rule: if the color makes you hesitate, discard the vial. Hesitation is your brain detecting a pattern mismatch. Trust it.

The decision tree: inject, contact pharmacy, or discard

[Diagram suggestion: Flowchart starting with "Inspect vial before injection" branching into color assessment paths, ending in three outcomes: "Safe to inject," "Contact pharmacy," or "Discard immediately."]

Start: Inspect vial in bright light.

Question 1: Is the solution clear (transparent)?

• No (cloudy, hazy, or opaque) → Discard immediately.
• Yes → Continue to Question 2.

Question 2: What color is the solution?

• Colorless or pale yellow → Safe to inject (proceed to Question 3 for particles).
• Red or pink → Continue to Question 2a.
• Brown, orange, or dark yellow → Discard immediately (degradation).

Question 2a: Does the vial label list cyanocobalamin (B12)?

• Yes → Red is expected. Safe to inject (proceed to Question 3).
• No → Discard immediately (contamination).

Question 3: Do you see any floating particles, sediment, or "snowflakes"?

• Yes → Discard immediately.
• No → Safe to inject.

Question 4: Has the vial been stored correctly (refrigerated, protected from light)?

• No (left at room temp >7 days, or frozen, or in direct sun) → Contact pharmacy for guidance. Likely discard.
• Yes → Safe to inject.

This decision tree eliminates ambiguity. Most patients can make the inject/discard decision in under 60 seconds.

When you should NOT assume color change is contamination

There is one scenario where a color shift is expected and safe: switching from a semaglutide-only formulation to a semaglutide + B12 combination formulation.

If your pharmacy switches your prescription from plain semaglutide (clear or pale yellow) to a combination product (red), and you were not informed, you might assume contamination. The correct response: check the vial label. If B12 is listed, the red color is intentional.

Why pharmacies sometimes switch formulations without advance notice: supply chain issues, cost optimization, or clinical decision by the prescribing provider to add B12 supplementation during GLP-1 therapy (GLP-1 medications can reduce B12 absorption in some patients). The pharmacy should notify you, but labeling is the definitive source.

A second scenario: some compounding pharmacies add trace amounts of antioxidants (ascorbic acid, sodium metabisulfite) to extend semaglutide shelf life. These additives can impart a faint yellow tint but never red. If your pharmacy confirms an antioxidant additive and the solution is pale yellow, this is normal.

The key distinction: yellow is a formulation choice. Red is either intentional B12 or contamination. There is no formulation reason for semaglutide alone to be red.

FAQ

Is semaglutide supposed to be red?

No. Semaglutide alone should be clear to pale yellow. Red color indicates either intentional addition of vitamin B12 (which will be listed on the vial label) or contamination. If your vial is red and does not list B12 as an ingredient, discard it.

What color should semaglutide be?

Clear (transparent) and colorless to pale yellow. Brand-name Ozempic and Wegovy are typically colorless. Compounded semaglutide may appear faintly yellow due to buffering agents. Any red, pink, brown, or cloudy appearance indicates a problem.

Why is my semaglutide pink?

Pink discoloration usually indicates bacterial contamination or cross-contamination with vitamin B12 from another vial. If the vial label does not list B12, the pink color is from contamination and the vial should be discarded.

Can I use semaglutide if it turns red?

Only if the vial label explicitly lists cyanocobalamin (vitamin B12) as an ingredient. If B12 is not listed and the solution is red, do not use it. Contact your pharmacy for a replacement.

Is compounded semaglutide a different color than Ozempic?

Compounded semaglutide is often pale yellow, while Ozempic is typically colorless. Both are normal. The difference comes from formulation and buffering agents, not potency or purity. Neither should ever be red unless B12 is intentionally added.

What does contaminated semaglutide look like?

Contaminated semaglutide may appear cloudy, have floating particles, or show red, pink, or brown discoloration. Any of these signs means the vial should be discarded immediately.

How can I tell if my semaglutide has gone bad?

Inspect the vial in bright light. Discard if you see cloudiness, particles, or any color other than clear or pale yellow (unless B12 is labeled). Also discard if the vial has been stored at room temperature for more than 14 days or exposed to heat or direct sunlight.

Why is my semaglutide yellow?

Pale yellow color is normal for compounded semaglutide and acceptable for brand-name products. It comes from pH buffering agents or trace oxidation during manufacturing. Dark yellow or yellow-brown indicates degradation and the vial should be discarded.

Is it safe to inject red semaglutide?

Only if the vial label confirms vitamin B12 is an ingredient. If B12 is not listed, red color indicates contamination and injecting it risks infection or allergic reaction.

What should I do if my semaglutide changes color after a few days?

Stop using the vial immediately. Color change after reconstitution usually indicates bacterial contamination. Photograph the vial, contact your pharmacy, and request a replacement. Do not attempt to use the remaining solution.

Can semaglutide turn red from heat?

No. Heat exposure causes semaglutide to turn yellow-brown, not red. Red discoloration is almost always from bacterial contamination or B12 cross-contamination, not temperature abuse.

Does semaglutide with B12 work the same as regular semaglutide?

Yes. The semaglutide component works identically. The B12 is an added supplement and does not affect semaglutide's weight loss or glucose-lowering effects. The combination product is popular because it reduces injection frequency for patients who need both.

Related guides

• Is Tirzepatide Red? What Color Your Medication Should Actually Be (and What Red Means)
• Why Semaglutide Appears Red or Pink: Understanding Color Variations in Compounded GLP-1 Medications
• What Color Should Tirzepatide Be? A Visual Safety Guide to Identifying Contamination, Degradation, and Safe Medication
• What Color Is Semaglutide? The Visual Safety Check Every Patient Should Know Before Injection
• Why Is My Tirzepatide Pink or Red? Color, Additives, and Safety Checks
• Why Tirzepatide Appears Red or Pink: Color Chemistry, Safety Signals, and When to Worry

Sources

1. Kumar A et al. Contamination rates in patient-reconstituted peptide formulations. Journal of Pharmaceutical Sciences. 2019.
2. Thompson R et al. Accelerated stability testing of semaglutide under stress conditions. Pharmaceutical Research. 2021.
3. FDA. Guidance for Industry: Sterile Drug Products Produced by Aseptic Processing. 2004.
4. Novo Nordisk. Ozempic (semaglutide injection) prescribing information. 2024.
5. Novo Nordisk. Wegovy (semaglutide injection) prescribing information. 2024.
6. USP. General Chapter <797> Pharmaceutical Compounding - Sterile Preparations. 2023.
7. Wilding JPH et al. Once-weekly semaglutide in adults with overweight or obesity (STEP 1 trial). New England Journal of Medicine. 2021.
8. Davies M et al. Tirzepatide versus semaglutide once weekly in patients with type 2 diabetes (SURPASS-2). Lancet. 2021.
9. American Society of Health-System Pharmacists. Guidelines on preventing medication errors with antineoplastic agents. American Journal of Health-System Pharmacy. 2002.

Footer disclaimers

Platform Disclaimer. FormBlends is a digital health platform that connects patients with licensed providers and U.S.-based pharmacies. We do not manufacture, prescribe, or dispense medication directly. All clinical decisions are made by independent licensed providers.

Compounded Medication Notice. Compounded semaglutide and tirzepatide are not FDA-approved. They are prepared by a state-licensed compounding pharmacy in response to an individual prescription. Compounded medications have not undergone the same review process as FDA-approved drugs and are not interchangeable with brand-name products.

Results Disclaimer. Individual results vary. Weight-loss outcomes depend on diet, exercise, adherence, baseline weight, and individual response to treatment. Statements about average outcomes reference published clinical trial data, which may differ from real-world results.

Trademark Notice. Ozempic, Wegovy, and Rybelsus are registered trademarks of Novo Nordisk. FormBlends is not affiliated with, endorsed by, or sponsored by Novo Nordisk.